Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Abingworth
AddedFeb 13, 2024
UpdatedJun 28, 2026
Abingworth

Abingworth

Acquired

Abingworth LLP: A transatlantic venture capital firm investing in bioscience, healthcare, and IT since 1973.

Location
London, Greater London, GB
Founded
1973
Firm
Compare
Portfolio
Employees
Website

Investments

Iambic Therapeutics
Iambic Therapeutics

Total Raised

$153M

Rounds

2

Series B$100MOctober 2023
Spruce Biosciences
Spruce Biosciences
Public

Total Raised

$161.6M

Rounds

4

Post Ipo Equity$53.6MFebruary 2023
Series B$88MFebruary 2020
Pathalys Pharma
Pathalys Pharma

Total Raised

$161M

Rounds

3

Series A$150MJanuary 2023
Entact Bio
Entact Bio

Total Raised

$120.9M

Rounds

2

Series A$81MDecember 2022
Escient Pharmaceuticals
Escient Pharmaceuticals
Public

Total Raised

$237.5M

Rounds

3

Series C$120MNovember 2022
Venatorx Pharmaceuticals
Venatorx Pharmaceuticals

Total Raised

$165.7M

Rounds

13

Series C$34MApril 2022
Series B$42MJuly 2017
CymaBay Therapeutics
CymaBay Therapeutics
Acquired

Total Raised

$710.2M

Rounds

16

Post Ipo Debt$100MAugust 2021
Wugen
Wugen

Total Raised

$172M

Rounds

2

Series B$172MJuly 2021
Glycomine
Glycomine

Total Raised

$80M

Rounds

3

Series B$35MJune 2021
X4 Pharmaceuticals
X4 Pharmaceuticals
Public

Total Raised

$542.9M

Rounds

14

Post Ipo Equity$55MMarch 2021
Scorpion Therapeutics
Scorpion Therapeutics

Total Raised

$270M

Rounds

2

Series B$162MJanuary 2021
Series A$108MOctober 2020
Atsena Therapeutics
Atsena Therapeutics

Total Raised

$87.6M

Rounds

3

Series A$55MDecember 2020
Q32 Bio
Q32 Bio

Total Raised

$106M

Rounds

2

Series B$60MOctober 2020
Series A$46MMay 2020
Nido Biosciences
Nido Biosciences

Total Raised

$109M

Rounds

3

Series A$18.4MSeptember 2020
Soleno Therapeutics
Soleno Therapeutics
Public

Total Raised

$160.5M

Rounds

4

Post Ipo Equity$16.5MDecember 2018
Gynesonics
Gynesonics
Public

Total Raised

$401.8M

Rounds

16

Private Equity$75MJanuary 2018
Series B$28.4MJuly 2014
Series D$21MFebruary 2013
Tizona Therapeutics
Tizona Therapeutics

Total Raised

$370M

Rounds

3

Series B$43MMarch 2016
Personalis
Personalis
Public

Total Raised

$225.1M

Rounds

5

Series C$33MJanuary 2015
Series B$22MOctober 2013